Immuneering Corp [IMRX] stock is trading at $1.80, up 9.09%. An important factor to consider is whether the stock is rising or falling in short-term value. The IMRX shares have gain 12.50% over the last week, with a monthly amount glided 5.26%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Immuneering Corp [NASDAQ: IMRX] stock has seen the most recent analyst activity on December 13, 2024, when Morgan Stanley downgraded its rating to a Underweight. Previously, Needham reaffirmed its Buy rating on March 15, 2024, and dropped its price target to $15. On March 15, 2024, downgrade downgraded it’s rating to Market Perform. Jefferies downgraded its rating to a Hold and decreased its price target to $3 on March 15, 2024. Needham initiated its recommendation with a Buy and recommended $20 as its price target on December 01, 2023. In a note dated April 19, 2023, Morgan Stanley upgraded an Equal-Weight rating on this stock and boosted its target price from $5 to $14.
Immuneering Corp [IMRX] stock has fluctuated between $1.00 and $3.83 over the past year. Currently, Wall Street analysts expect the stock to reach $17.5 within the next 12 months. Immuneering Corp [NASDAQ: IMRX] shares were valued at $1.80 at the most recent close of the market. An investor can expect a potential return of 872.22% based on the average IMRX price forecast.
Analyzing the IMRX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -1.16, Equity is -1.0 and Total Capital is -1.42. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.5735 points at the first support level, and at 1.3471 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.9682, and for the 2nd resistance point, it is at 2.1365.
Ratios To Look Out For
For context, Immuneering Corp’s Current Ratio is 5.28. On the other hand, the Quick Ratio is 5.28, and the Cash Ratio is 4.82.
Transactions by insiders
Recent insider trading involved Cormorant Asset Management, LP, 10% Owner, that happened on Apr 01 ’24 when 0.4 million shares were sold.
